Katie Ellard
CellCentric (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Cytokine Signaling Pathways and Interactions, Quinazolinone synthesis and applications, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) Interaction(2010)195 cited
- → A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation(2012)143 cited
- → SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors(2012)49 cited
- → A Selective Inhibitor Reveals Pi3Kgamma Dependence of T(H)17 Cell Differentiation.(2012)24 cited
- → Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease(2012)24 cited
- → Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation(2012)18 cited
- → CZ415, a Highly Selective mTOR Inhibitor Showing in Vivo Efficacy in a Collagen Induced Arthritis Model(2016)15 cited
- → Erratum: Corrigendum: A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation(2012)4 cited
- → ChemInform Abstract: Discovery of 5‐(2‐Amino‐[1,2,4]triazolo [1,5‐a]pyridin‐7‐yl)‐N‐(tert‐butyl)pyridine‐3‐sulfonamide (CZC24758), as a Potent, Orally Bioavailable and Selective Inhibitor of PI3K for the Treatment of Inflammatory Disease.(2012)